Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Malignancies
Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1 clinical trial examining the safety, pharmacokinetics and pharmacodynamics
of escalating doses of the proteasome inhibitor NPI-0052 in patients with advanced
malignancies including solid tumors, lymphomas, leukemias and multiple myeloma. By inhibiting
proteasomes NPI-0052 prevents the breakdown of proteins involved in signal transduction,
which blocks growth and survival in cancer cells.
Phase:
Phase 1
Details
Lead Sponsor:
Celgene Triphase Research and Development I Corporation